top of page

North Macedonian medical cannabis disruptor with EU-GMP compliant facility and proprietary digital platform/IP seeks investment partner

A UK-based ownership group, with North Macedonia's EU-GMP compliant manufacturing facility, boasts exclusive manufacturing capability, a proprietary digital platform, and an industry-leading low-cost structure. Company seeks €2.5 million investment to finalize EUGMP compliance and launch their first products into European and global markets

Listing ID:

18598094464

Licence(s) Held:

Regulatory license held for the manufacturing, R&D, processing, packaging and import/ export of medicinal cannabis globally includes flower, extracts and final product

18598094464

Seeking strategic investment of €2.5 million

Listing Details:

  • Headquarted in London, UK, this medical cannabis company strategically leverages a low-cost manufacturing facility in North Macedonia to access the supply chain, while maintaining its focus on higher-value activities further along the chain

  • Construction completed on a ~2,500 m² EU GMP designed manufacturing, R&D, processing and packaging facility

  • Facility is capable of tolling 1000 KG’s of dried flower per month (i.e. GACP to GMP conversion), extraction capacity of 130 lts per month (EU-GMP) and further capabilities for packaging, white labeling, finished product, and stability chambers

  • 25 acres of commercial land owned and 5 acres are licensed for production and outdoor cultivation

  • Company has developed proprietary platforms for wholesale (i.e. suppliers, distributors), end patient (i.e. patients and prescribers) clinician evidence, and data/ IA platforms.

  • World-class team with domain and industry leadership spanning medical, pharmaceuticals, technology and cannabinoids

  • Have established a number of key relationships with clinics, distributors, university partners and other commercial partners

  • Diversified supply agreements are in place and multiple LOIs/contracts are underway

  • Exclusive partnership for core set of stable genetics

  • With a portfolio comprising 12 vaporized formulations, the company is poised to lead the medical cannabis vaporizer market through exclusive partnership with leading UK Clinic & German distributor; targeting launches in the UK, German, and Australian markets

  • Anticipating ~€4 million in annual revenue in 2024

  • Exclusive contract for the cultivation and supply to a UK cannabinoid FDA Botanical Pathway Drug Development company

  • Strategically positioned as a key gateway for importing and exporting cannabis and cannabis products to and from North Macedonia, poised to emerge as a prominent force in pioneering cannabinoid-based medication and technology within Europe

  • The company seeks €2.5 million investment to achieve EU-GMP certification and introduce its unique products into the European and global markets

18598094464

Inquiry Form

Thanks for submitting! We have received your message and will get back to you within 24 hours. Until then, you can send an email to info@hydeadvisory.com

Contact-us-deal
bottom of page